Next-generation sequencing (NGS) has transformed the landscape of hematological malignancy testing, yet challenges remain in achieving comprehensive, rapid, and actionable results. To address these limitations, a novel hybridization capture-based NGS assay has been developed, enabling simultaneous interrogation of DNA mutations—including SNVs, INDELs, CNVs, IGH fusions, and FLT3 ITDs—as well as chimeric RNA fusions. This innovative technology covers gene mutations essential in both lymphoid and myeloid cancers and leverages laboratory and informatics automation to streamline the entire workflow. The SureSelect Cancer Pan Heme Assay delivers sample-to-result testing in under three days, minimizing traditional NGS limitations by comprehensively targeting all heme-related genes and integrating automated solutions for expedited and reliable reporting. Learning objectives Discover the advantages of a comprehensive NGS-based pan-heme assay • Participants will understand how the SureSelect Cancer Pan Heme Assay enables broad molecular profiling of hematologic malignancies, including the detection of diverse mutation types across all relevant genes. • Participants will recognize how the solution enhances clinical decision-making and research by providing rapid, accurate, and comprehensive molecular information for hematologic cancers. Explore integrated informatics and automation solutions • Participants will learn how automation in the laboratory workflow accelerates turnaround times and ensures consistency in results. • Participants will gain insights into the informatics platforms that support the assay, including automated data analysis and reporting.